The Washington Business Journal article tells the story of the evolution of Immunomic Therapeutics and its strategy
in applying LAMP-Vax in dierent disease areas. The article further highlights Immunomics partnering successes, led by CEO, Dr. Bill Hearl. In particular, the article explains how Immunomic focused on Japanese Red Cedar and allergy, gained some initial data, licensed it to Astellas, and then grew the relationship with Astellas to an exclusive Worldwide license for all allergy applications of LAMP. Now, Immunomic has pivoted into applying LAMP-Vax in oncology. The article also provides some information about the work going on at University of Florida in Glioblastoma that incorporates LAMP-Vax technology.